ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Discover Why Ashwagandha Can Be Used for Stress and Anxiety

How Can You Benefit From Vitamin B12?

Calorie restriction promotes longevity through effects on mitochondrial network

Lower magnesium levels linked with increased mortality risk during up to 40 years of follow-up

Higher resveratrol dose linked to lower glucose levels in type 2 diabetics

What Is Bitter Orange?

Black Tea Is Great for Your Gut

Drug can dramatically reduce weight of people with obesity

Tryptophan's Possible Effects for Your Health

New Finding: Broccoli Helps Heal Leaky Gut

 
Print Page
Email Article

Alzheimer's Disease Patients Show Improved Cognition and Global Function with Aricept

  [ 69 votes ]   [ Discuss This Article ]
www.ProHealth.com • February 25, 2002




New Research shows Aricept® (donepezil hydrochloride) maintained or improved cognition and global function in Alzheimer's disease patients who resided in nursing homes. This is according to study results published in the December 2001 issue of the Journal of the American Geriatrics Society.

The efficacy of Aricept® in nursing home patients was similar to previously reported results in studies of outpatients with mild to moderate Alzheimer's disease. The findings suggest that advanced age, co-morbid illnesses, and high concomitant medication usage should not be barriers to treatment with the medication. However the study authors suggest that appropriate precautions should be taken when treating such patients with Aricept®.

"These findings offer patients, their families and the medical community evidence that Alzheimer's disease can be effectively treated and managed in the nursing home setting," said Pierre N. Tariot, MD, study investigator and professor of psychiatry, University of Rochester (New York) School of Medicine. "In demonstrating that age or residence in a nursing home are not barriers to treatment for Alzheimer's disease, this study emphasizes the need to raise awareness among nursing home staff of the disease and its symptoms."

The multicenter, double-blind placebo-controlled study examined 208 nursing home patients with an average age of 85, and possible or probable Alzheimer's disease to determine the efficacy, safety, and tolerability of Aricept treatment. The average MMSE(I) score of 14.4 for patients in the study indicated dementia in the moderate range at baseline.

Consistent with previous studies, Aricept® was generally well tolerated in this population despite advanced patient age and high use of other medications.

"It is important not to dismiss memory problems as just 'normal aging'," continued Tariot. "Recognizing symptoms of dementia and getting an early diagnosis give patients a greater chance of benefiting from medical interventions, including treatment with medications such as Aricept®."

During the 6-month trial, the 208 patients were evaluated on the NPI-NH(II) and MMSE every 4 weeks, and every 12 weeks on the Clinical Dementia Rating-Sum of the Boxes (CDR-SB), which was adapted for use in the nursing home setting. The CDR-SB is scored based on interviews with both the caregiver and the patient, and provides an overall or global measure of dementia severity, based on items to assess both cognition and patient function. These items include memory, orientation, judgment and problem solving, community affairs, home life in room and hobbies and personal care.

Patients in the active group received 5 mg of Aricept® once daily for the first 4 weeks and 10 mg once daily for the remaining 20 weeks. Average NPI-NH total scores improved in both groups relative to baseline at all assessments with no statistically significant differences.

Differences in mean change from baseline scores for the MMSE favored Aricept® treated patients over placebo at all time points, and were statistically significant at weeks 8, 16 and 20. Differences in average change from baseline on the CDR-SB favored Aricept® at both weeks 12 and 24. At week 24, Aricept®-treated patients tended to improve on both cognitive and functional items of the CDR-SB compared with those receiving placebo.

Weight loss, abdominal pain, nausea, tremor and muscle weakness were reported more frequently in Aricept® treated patients. The occurrence of bradycardia (slow heartbeat) was similar for the two treatment groups. Adverse events were generally mild in intensity, transient, and similar to those reported previously in outpatient studies.



Post a Comment

Featured Products From the ProHealth Store
FibroSleep™ Ultra EPA  - Fish Oil Mitochondria Ignite™ with NT Factor®


Article Comments



Be the first to comment on this article!

Post a Comment


 
Optimized Curcumin Longvida with Omega-3

Featured Products

Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%

Natural Remedies

Break Free From Fibromyalgia Break Free From Fibromyalgia
Physically and Mentally Exhausted? How to Restore Energy at Its Source Physically and Mentally Exhausted? How to Restore Energy at Its Source
Block Acid Reflux to Prevent Esophageal Problems! Block Acid Reflux to Prevent Esophageal Problems!
The Surprising Benefits of Probiotics - What You Didn't Know The Surprising Benefits of Probiotics - What You Didn't Know
Enhance Eyelashes Naturally Enhance Eyelashes Naturally

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map